English  |  正體中文  |  简体中文  |  2856655  
???header.visitor??? :  53565228    ???header.onlineuser??? :  1062
???header.sponsordeclaration???
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
???ui.leftmenu.abouttair???

???ui.leftmenu.bartitle???

???index.news???

???ui.leftmenu.copyrighttitle???

???ui.leftmenu.link???

"sequist l v"???jsp.browse.items-by-author.description???

???jsp.browse.items-by-author.back???
???jsp.browse.items-by-author.order1??? ???jsp.browse.items-by-author.order2???

Showing items 11-20 of 40  (4 Page(s) Totally)
<< < 1 2 3 4 > >>
View [10|25|50] records per page

Institution Date Title Author
臺大學術典藏 2020-05-26T09:27:07Z Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial Miller V.A.;Yang P.-C;Lorence R.M;Cong X.J;Shahidi M;Dudek A.Z;Sequist L.V;Ho C.-L;Chang G.-C;Yu C.-J;Ou S.H.I;Tsai C.-M;Hsia T.-C;Su W.-C;Shih J.-Y;Chih-Hsin Yang; CHIH-HSIN YANG; Shih J.-Y; Su W.-C; Hsia T.-C; Tsai C.-M; Ou S.H.I; Yu C.-J; Chang G.-C; Ho C.-L; Sequist L.V; Dudek A.Z; Shahidi M; Cong X.J; Lorence R.M; Yang P.-C; Miller V.A.
臺大學術典藏 2020-05-26T09:27:06Z Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1 Chmielecki J; Lin Y.-L; Pan Y; Wang L; De Stanchina E; Shien K; Aoe K; Toyooka S; Kiura K; Fernandez-Cuesta L; Fidias P; CHIH-HSIN YANG; Miller V.A; Riely G.J; Kris M.G; Engelman J.A; Vnencak-Jones C.L; Dias-Santagata D; Ladanyi M; Pao W.; Pao W.;Ladanyi M;Dias-Santagata D;Vnencak-Jones C.L;Engelman J.A;Kris M.G;Riely G.J;Miller V.A;Chih-Hsin Yang;Fidias P;Fernandez-Cuesta L;Kiura K;Toyooka S;Aoe K;Shien K;De Stanchina E;Wang L;Pan Y;Lin Y.-L;Chmielecki J;Moran T;Arcila M.E;Sequist L.V;Ohashi K; Ohashi K; Sequist L.V; Moran T; Arcila M.E
臺大學術典藏 2020-05-26T09:27:01Z Symptom control and quality of life in lux-lung 3: A phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations Chih-Hsin Yang;Hirsh V;Schuler M;Yamamoto N;O'Byrne K.J;Mok T.S.K;Zazulina V;Shahidi M;Lungershausen J;Massey D;Palmer M;Sequist L.V.; CHIH-HSIN YANG; Hirsh V; Schuler M; Yamamoto N; O'Byrne K.J; Mok T.S.K; Zazulina V; Shahidi M; Lungershausen J; Massey D; Palmer M; Sequist L.V.
臺大學術典藏 2020-05-26T09:27:01Z Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations Sequist L.V;Chih-Hsin Yang;Yamamoto N;O'Byrne K;Hirsh V;Mok T;Geater S.L;Orlov S;Tsai C.-M;Boyer M;Su W.-C;Bennouna J;Kato T;Gorbunova V;Lee K.H;Shah R;Massey D;Zazulina V;Shahidi M;Schuler M.; Sequist L.V; CHIH-HSIN YANG; Yamamoto N; O'Byrne K; Hirsh V; Mok T; Geater S.L; Orlov S; Tsai C.-M; Boyer M; Su W.-C; Bennouna J; Kato T; Gorbunova V; Lee K.H; Shah R; Massey D; Zazulina V; Shahidi M; Schuler M.
臺大學術典藏 2020-05-26T09:26:58Z Reply to E.R. Haspinger et al Chih-Hsin Yang;Sequist L.V.; CHIH-HSIN YANG; Sequist L.V.
臺大學術典藏 2020-05-26T09:26:58Z Reply to F. de Marinis et al Chih-Hsin Yang;Sequist L.V.; CHIH-HSIN YANG; Sequist L.V.
臺大學術典藏 2020-05-26T09:26:57Z Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: A combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6 CHIH-HSIN YANG; Sequist L.V; Geater S.L; Tsai C.-M; Mok T.S.K; Schuler M; Yamamoto N; Yu C.-J; Ou S.H.I; Zhou C; Massey D; Zazulina V; Wu Y.-L.; Wu Y.-L.;Zazulina V;Massey D;Zhou C;Ou S.H.I;Yu C.-J;Yamamoto N;Schuler M;Mok T.S.K;Tsai C.-M;Geater S.L;Sequist L.V;Chih-Hsin Yang
臺大學術典藏 2020-05-26T09:26:54Z Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): Analysis of overall survival data from two randomised, phase 3 trials Sequist L.V.;Zazulina V;Shahidi M;Massey D;Kato T;Lee K.H;Su W.-C;Boyer M;Mok T;Orlov S;Bennouna J;Hirsh V;Gorbunova V;Tsai C.-M;Lee K.Y;Geater S.L;Huang Y;Lu S;Feng J;O'Byrne K;Hu C.-P;Zhou C;Yamamoto N;Popat S;Sebastian M;Schuler M;Wu Y.-L;Chih-Hsin Yang; CHIH-HSIN YANG; Wu Y.-L; Schuler M; Sebastian M; Popat S; Yamamoto N; Zhou C; Hu C.-P; O'Byrne K; Feng J; Lu S; Huang Y; Geater S.L; Lee K.Y; Tsai C.-M; Gorbunova V; Hirsh V; Bennouna J; Orlov S; Mok T; Boyer M; Su W.-C; Lee K.H; Kato T; Massey D; Shahidi M; Zazulina V; Sequist L.V.
臺大學術典藏 2020-05-26T09:26:51Z Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: Post hoc analyses of the randomized LUX-Lung 3 and 6 trials Shah R; Märten A; Massey D; Wind S; Wu Y.-L.; Dickgreber N; Okamoto I; Sebastian M; Huang Y; Hirsh V; Lu S; O'Byrne K; Feng J; Wu Y.-L.;Wind S;Massey D;M?rten A;Shah R;Dickgreber N;Okamoto I;Sebastian M;Huang Y;Hirsh V;Lu S;O'Byrne K;Feng J;Yamamoto N;Hu C.-P;Mok T;Geater S.L;Schuler M;Zhou C;Sequist L.V;Chih-Hsin Yang; CHIH-HSIN YANG; Sequist L.V; Zhou C; Schuler M; Geater S.L; Mok T; Hu C.-P; Yamamoto N
臺大學術典藏 2020-05-26T09:26:48Z First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases Chih-Hsin Yang;Zazulina V;Massey D;Sequist L.V;Popat S;Mok T;Yamamoto N;O'Byrne K;Hirsh V;Wu Y.-L;Schuler M; Schuler M; Wu Y.-L; Hirsh V; O'Byrne K; Yamamoto N; Mok T; Popat S; Sequist L.V; Massey D; Zazulina V; CHIH-HSIN YANG

Showing items 11-20 of 40  (4 Page(s) Totally)
<< < 1 2 3 4 > >>
View [10|25|50] records per page